Pharmaceutical Venture

Only available on StudyMode
  • Download(s) : 134
  • Published : April 5, 2013
Open Document
Text Preview
Acknowledgement

“Gratitude is the hardest of emotions to express and often does not find adequate ways to convey the entire one feels.”

For this with an ineffable sense of gratitude we take this opportunity to express our deepest sense of indebtedness to Respected Dr. Vidya Hatangadi, Director, of the Gurunanak Institute of Management Studies, who has provided us this opportunity which has helped us to gain insight on the oncology sector in India during our MMS course. At the same time, we want to thank all our faculty members.

We would have never been able to complete our project without the enormous help extended by the whole staff of our college professor of Guru Nanak Institute of Management Studies.

GROUP MEMBERS
Sr No.| Roll No.| Name|
1| A-06| Harpreet Singh |
2| A-11| Karan Doshi|
3| A-20| Supriya Hegde|
4| A-24| Gurbaani Kaur|
5| A-27| Angad Madan|
6| A-33| Nandan Masurkar|
7| A-41| Neha Panchal|
8| A-43| Shruti Pandey|
9| A-50| Girish Shetty|
10| A-58| Vedant Worlikar|
11| B-22| Jidnyasa Kulkarni|
12| B-33| Sharan Nottay|
13| PG-01| Aalam Musharraf|
14| PG-12| Karanvir Gujral|

TABLE OF CONTENTS
S.No.| CHAPTERS| PAGE. NO.|
| OVERVIEW – INDIAN PHARMACEUTICALINDUSTRY| |
1.1| Current Scenario| 6|
1.2| Major Pharmaceutical Companies| 10|
1.3| Government Initiatives| 12|
1.4| Oncology Segment| 15|
| LUNG CANCER| |
2.1| World Scenario| 21|
2.2| Indian Scenario| 22|
2.3| About Lung Cancer| 30|
2.4| Stages of Lung Cancer| 36|
2.5| Causes of Lung Cancer| 46|
| LONG LIFE PHARMACEUTICALS PVT. LTD.| |
3.1| Vision and Mission| 48|
3.2| Board of Directors| 49|
3.3| Contract Manufacturing| 50|
3.4| Suppliers| 53|
3.5| Product Range| 56|
3.6| Price| 60|
3.7| Place| 61|
3.8| Promotion| 63|
3.9| 5 Force Model| 66|
4.0| SWOT Analysis| 69|
4.1| PEST Analysis| 71|
4.2| Balance Sheet| 76|
4.3| Future Prospects| 82|
4.4| Memorandum of Association| 83|
4.5| Articles of Association| 89|
4.6| Bibliography| 104|

Indian Pharmaceutical Industry – An Overview
The Indian pharmaceutical Industry, driven by knowledge, skills, low production costs and international quality products, has witnessed a robust growth from the production turnover of about Rs. 5000 crores in 1990 to over Rs1lakh crores in 2009‐10 comprising about Rs, 62,055 crores of domestic market and Rs. 42,154 crores of exports. It is, globally, the 3rd largest producer of medicines by volume yet 14th in terms of value. The Indian pharmaceutical industry is growing at about 8 to 9 percent annually according to “A Brief Report Pharmaceutical Industry in India,” published in January 2011. The Pharmaceutical industry in India meets around 70% of the country's demand for bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and injectables. There are approximately 250 large units and about 8000 Small Scale Units, which form the core of the pharmaceutical industry in India (including 5 Central Public Sector Units).  The demand for pharmaceutical products in India is significant and is driven by low drug penetration, rising middle-class & disposable income, increased government & private spending on healthcare infrastructure, increasing medical insurance penetration etc.   

I. Current Scenario: 
 
India's pharmaceutical market grew at 15.7 per cent during December 2011. Globally, India ranks third in terms of manufacturing pharmaceutical products by volume. According to McKinsey, the Pharmaceutical Market is ranked 14th in the world. By 2015 it is expected to reach top 10 in the world beating Brazil, Mexico, South Korea and Turkey. More importantly, the incremental market growth of US$ 14billion over the next decade is likely to be the third largest among all markets. The US and China are expected...
tracking img